Cortex’ Clinical Hold On CX717 Lifted By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company may resume clinical trials of the compound, which it has studied for Alzheimer's disease and attention deficit/hyperactivity disorder.